中药注射剂安全性问题文献研究 点击下载
论文标题: 中药注射剂安全性问题文献研究
英文标题:
中文摘要: 目的:为中药注射剂临床合理应用提供参考。方法:通过中国期刊全文数据库(CNKI)、中文科技期刊数据库(VIP)、万方数据知识服务平台、PubMed文献数据库,检索国家食品药品监督管理总局(CFDA)ADR监测2014年度报告数量排名前10位的中药注射剂近30年的文献全文报道。采用文献回顾性研究,分析中药注射剂药品不良反应(ADR)/药品不良事件(ADE)案例。结合上市后药物再评价安全性及合理性研究,评价其临床用药安全问题。结果:共检索到文献2 013篇,纳入1 354篇。中药注射剂ADR常累及多器官/系统,其中尤以心血管系统、呼吸系统、皮肤及附件居多;引发ADR/ADE的主要以理血类功效的中药注射剂居多;临床表现以过敏反应最多,其中严重的ADR主要表现为过敏性休克。引发ADR/ADE的10种中药注射剂的原发病、溶剂、给药浓度合理率及配伍应用情况与说明书一致性普遍偏低,其中,原发病符合率为78.30%,溶剂种类一致率为77.94%,给药浓度一致率为74.64%,81.73%为单独配伍。结论:中药注射剂ADR/ADE较为严重,亟需从安全性及合理性方面完善其上市后再评价方案。
英文摘要: OBJECTIVE: To provide reference for rational use of TCM injection in the clinic. METHODS:  Retrieved from CNKI, VIP, Wanfang database and PubMed database, literatures about top 10 TCM injections in the list of report number stated in 2014 CFDA ADR monitoring report were researched in recent 30 years. By literature retrospective study, ADR/ADE induced by TCM injection were analyzed. Combining with post-marketing drug safety re-evaluation and rationality study, the security of clinical use of TCM injection was evaluated. RESULTS: A total of 2013 literatures were retrieved, 1 354 were. Most organs or systems were involved in ADR, especially cardiovascular system, respiratory system, skin and its appendants. Allergic reaction was main clinical manifestation, among which server ADR was allergic shock. Ten ADR/ADE-inducing TCM injections had the lower consistency with instructions in the original diseases, solvent, dosage concentration and compatibility application. Consistency rate of original diseases, solvent and dosage concentration was 78.30%, 77.94% and 74.64%; 81.73% of them were used individually. CONCLUSIONS: ADR/ADE induced by TCM injection is serious. It is urgent to improve post-marketing revaluation scheme from the aspects of safety and rationality.
期刊: 2017年第28卷第11期
作者: 杨洪军,于振兰
英文作者: YANG Hongjun,YU Zhenlan
关键字: 中药注射剂;不良反应;文献;安全用药;用药评价
KEYWORDS: TCM injections; ADR; Literature; Safe medication; Evaluation of durg use
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!